Author: Oghbaei, Farnaz ; Fattahi, Amir ; Khodavirdilou, Rasa ; Laleh, Sanya Hayati ; Amorim, Christiani A. ; Latifi, Zeinab ; Nejabati, Hamid R. ; Zarezadeh, Reza ; Nikanfar, Saba ; Khodavirdilou, Lida

Polycystic ovary syndrome (PCOS) is a primary endocrinological disorder in women of reproductive age that is characterized by androgen excess and ovulatory irregularities. This syndrome is associated with adipose tissue dysfunction, an elevated risk of insulin resistance, hyperinsulinemia, obesity, and type 2 diabetes. Adipocyte dysfunction affects the secretion of adipokines and pro-inflammatory cytokines. Nevertheless, adipose tissue is not an exclusive source of adipokines as it can also be produced locally by reproductive tissues. Although adipokines have been recognized in the development of PCOS, the role of oncostatin M (OSM), a multifaceted adipokine, remains unclear. Current evidence suggests that this cytokine is associated with key aspects of the syndrome, including obesity, insulin resistance, hyperandrogenism, and inflammation. However, the data are often contradictory, likely due to variations in study designs, methodologies, and species differences. By investigating the link between OSM and PCOS-associated issues, this review identified the potential role of this adipokine in PCOS pathogenesis. This underscores the need for further research to clarify its predominant effects and assess its relevance as a therapeutic target.

01 Sep 2024·Journal of Periodontology

Gingipain and oncostatin M synergistically disrupt kidney tight junctions in periodontitis‐associated acute kidney injury

Article

Author: Hu, Jiangqi ; Jiang, Qingsong ; Sun, Jing ; Ji, Zhaoxin ; Wei, Wei

AbstractBackgroundAcute kidney injury (AKI) is characterized by rapid renal decline. Periodontitis, a chronic oral inflammatory disease, is increasingly associated with renal dysfunction. Although periodontitis is recognized as a contributor to kidney damage, the mechanisms linking it to AKI remain unclear.MethodsThis study explored the effects of Porphyromonas gingivalis (P. gingivalis) W83‐infected periodontitis on AKI in C57BL/6J mice, using ischemia‐reperfusion injury 55 days post‐infection. Gingipain inhibitors, KYT‐1 and KYT‐36, were applied. Detection of P. gingivalis was performed using quantitative real‐time polymerase chain reaction (qRT‐PCR) and PCR, while transcriptome sequencing, qRT‐PCR, immunohistochemistry, and immunofluorescence staining assessed renal damage. In vitro, HK‐2 cells were exposed to P. gingivalis at a multiplicity of infection of 10 for 48 h, with inhibition by gingipain or oncostatin M (OSM). Disruption of tight junctions (TJs) was quantified using qRT‐PCR, transepithelial electrical resistance, and cell counting kit‐8 assays.ResultsPeriodontitis worsened AKI, linked to P. gingivalis infection and renal TJ disruption in the kidney. P. gingivalis infection activated OSM expression, which correlated positively with gingipain. Significantly, OSM and gingipain might collaboratively contribute to the damage of renal TJs, with the reduced expression of TJ proteins. Suppressing gingipain activity presented itself as a protective strategy against the destruction of TJs and the attendant worsening of AKI due to periodontitis.ConclusionsOur study enhances the understanding of the interplay between periodontitis and AKI, highlighting the harmful impact of P. gingivalis in AKI.

100 Deals associated with Oncostatin M

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Immunologic Deficiency Syndromes	Phase 2	US	Bristol Myers Squibb Co.	-
Neoplasms	Phase 2	US	Bristol Myers Squibb Co.	-
Retinal Neovascularization	Preclinical	DE	University of Freiburg	01 May 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EASD2022	Not Applicable	-	-	oncostatin-M	wpschzdvth(xfyqordwcg) = +47% yyucxzwwun (gbzsmngijo ) View more	Positive	21 Sep 2022
				oncostatin-M

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Oncostatin M

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation